<DOC>
	<DOC>NCT00281008</DOC>
	<brief_summary>The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia</brief_summary>
	<brief_title>Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Weight â‰¥ 50 kg Diagnosis of Heterozygous Familial Hypercholesterolemia. Females must be nonpregnant and nonlactating. On stable lipid lowering therapy for at least 4 weeks. Lipid levels meet the prespecified criteria. Subject had heart problems in the prior 6 months. Subject has elevated ALT, AST, or CPK. History of renal disease, liver disease, or malignancy. Use of oral anticoagulants, unless the dose has been stable for 4 weeks Have any other conditions, which in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in or completing the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LDL-cholesterol</keyword>
	<keyword>apoB-100</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
</DOC>